Alice Cani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1661233/publications.pdf

Version: 2024-02-01

840119 940134 20 572 11 16 citations h-index g-index papers 20 20 20 1082 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia, 2014, 28, 739-748.	3.3	107
2	miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Molecular Therapy - Nucleic Acids, 2018, 11, 485-493.	2.3	81
3	Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia, 2012, 26, 2336-2342.	3.3	76
4	Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget, 2014, 5, 10034-10047.	0.8	60
5	The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy. Oncotarget, 2013, 4, 1496-1506.	0.8	47
6	Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 883-887.	1.4	33
7	The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget, 2015, 6, 17147-17160.	0.8	30
8	HIF- $1\hat{l}$ =/Wnt signaling-dependent control of gene transcription regulates neuronal differentiation of glioblastoma stem cells. Theranostics, 2019, 9, 4860-4877.	4.6	29
9	Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 6597-6610.	0.8	27
10	Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course. Blood, 2021, 138, 557-570.	0.6	26
11	Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. Human Mutation, 2018, 39, 579-587.	1.1	16
12	Hydrogen peroxide toxicity on auditory cells: An in vitro study. Chemico-Biological Interactions, 2021, 345, 109575.	1.7	11
13	Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation. Cancers, 2022, 14, 1897.	1.7	11
14	Effects of Ultra-Short Pulsed Electric Field Exposure on Glioblastoma Cells. International Journal of Molecular Sciences, 2022, 23, 3001.	1.8	7
15	Case Report: Intestinal Nodular Lymphoid Hyperplasia as First Manifestation of Activated PI3Kδ Syndrome Due to a Novel PIK3CD Variant. Frontiers in Pediatrics, 2021, 9, 703056.	0.9	5
16	Customized bioreactor enables the production of 3D diaphragmatic constructs influencing matrix remodeling and fibroblast overgrowth. Npj Regenerative Medicine, 2022, 7, 25.	2.5	5
17	Abstract 3750: The novel Akt inhibitor MK-2206, is cytotoxic in T-cell acute lymphoblastic leukemia: Therapeutic implications., 2012, , .		1
18	Abstract 3736: The mTOR inhibitor, RAD001, displays higher cytotoxicity in leukemias with hyperactivated PI3K/AKT/mTOR pathway., 2012,,.		0

#	Article	lF	CITATIONS
19	Abstract B46: Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent AKT reactivation. , 2015, , .		O
20	Abstract A34: Therapeutic potential of the novel mTOR inhibitor Torin-2 to overcome AKT reactivation in B-precursor acute lymphoblastic leukemia (B-pre ALL), 2015, , .		0